Core Insights - Incannex Healthcare Inc. has entered a Partnership Agreement with the AASM Foundation, joining its Corporate Recognition Program and sponsoring a grant for Junior Investigators focused on sleep apnea research [1][5] - The partnership underscores the company's commitment to the sleep medicine community while advancing its investigational treatment IHL-42X for obstructive sleep apnea (OSA) [2][6] Company Developments - Incannex is developing IHL-42X, a first-in-class oral fixed-dose combination of dronabinol and acetazolamide, targeting the underlying mechanisms of OSA, a condition affecting hundreds of millions globally [3][8] - The past year has seen significant milestones for Incannex, including the initiation of the DReAMzz study aimed at optimizing the active ingredient ratio in IHL-42X, with patient dosing expected to commence soon [4][6] - Positive Phase 2 clinical trial results have shown statistically significant improvements in OSA outcomes, validating IHL-42X's therapeutic potential [6] - The FDA has granted Fast Track designation to IHL-42X, facilitating a more collaborative and expedited development pathway [6] Research and Community Engagement - As a sponsor of the AASM Foundation's Focused Projects Grant, Incannex will support independent research into the diagnosis, management, and treatment of sleep apnea, with the grant to be awarded in 2026 [5][6] - The partnership will involve collaborative efforts in press releases, digital promotion, and social media to enhance awareness of the research supported by Incannex [5]

Core Insights - Aemetis, Inc. announced that its CEO, Eric McAfee, received the 2026 William C. Holmberg Memorial Award for Lifetime Achievement in the Bioeconomy, recognizing his contributions to renewable fuels [1][2][3] Company Overview - Aemetis is a diversified renewable natural gas and biofuels company headquartered in Cupertino, California, focused on innovative technologies that lower energy costs and reduce emissions [5] - The company operates a biogas digester network and pipeline system in California, converting dairy waste gas into Renewable Natural Gas [5] - Aemetis owns a 65 million gallon per year ethanol production facility in California's Central Valley, supplying about 80 dairies with animal feed [5] - The company also operates an 80 million gallon per year biodiesel production facility on the East Coast of India, producing high-quality biodiesel and refined glycerin [5] - Aemetis is developing a sustainable aviation fuel plant and a CO2 sequestration project in California to utilize byproducts from ethanol production [5] Industry Recognition - Eric McAfee's acceptance speech highlighted the collaborative efforts of the Aemetis team and industry colleagues in advancing renewable fuels policy and production [3][4] - The award honors the legacy of William C. Holmberg, a significant advocate for energy security and renewable fuels [3]

Core Viewpoint - Flyte is expanding its Vision Jet-powered Hops platform to establish a new standard in regional travel, focusing on safety, speed, efficiency, and affordability [1][2] Company Overview - Flyte operates a growing fleet of Cirrus Vision Jets, targeting high-frequency, short-haul markets to provide a faster, safer, and more efficient alternative to traditional private charter travel [5][6] Product and Service Features - The Hops platform is designed for flights under approximately 500 miles, addressing inefficiencies in traditional private aviation [3] - Key features of the Vision Jet include: - Private terminal access to eliminate TSA delays and reduce travel time - Rapid booking-to-boarding timelines for near on-demand travel - Right-sized aircraft economics for lower operating costs compared to larger jets - High-frequency route capability for scalable short-haul travel - AI-driven scheduling and pricing optimization to enhance fleet utilization and customer experience [4][8] Competitive Positioning - Flyte differentiates itself from legacy charter operators by optimizing its platform for short-haul missions rather than larger aircraft and longer routes [3] - The model aims to transform private aviation from a luxury service into a practical regional transportation solution [4] Growth Strategy - Flyte is actively expanding its Vision Jet fleet and geographic footprint, focusing on high-density regional travel corridors across the United States [3][4] - The strategy includes: - Fleet expansion aligned with demand growth - Development of high-frequency regional routes - Continued investment in AI-driven operations and pricing - Strategic partnerships to accelerate customer acquisition [4]

Core Viewpoint - Skyharbour Resources Ltd. has made significant leadership changes by appointing Rob Chang as an Independent Director and Amanda Chow as Chief Financial Officer, which reflects the company's growth potential and strategic direction in the uranium sector [1][4][3] Leadership Appointments - Rob Chang brings nearly 30 years of experience in financial services, particularly in uranium and mining, and has held prominent positions including co-founder and CEO of Gryphon Digital Mining [1][2] - Amanda Chow, a Chartered Professional Accountant with over 25 years of experience, has been appointed as CFO after serving as a Director at Skyharbour [3][4] Company Strategy and Operations - The company is currently undertaking its largest annual drilling campaign of over 30,000 meters at its Athabasca project portfolio, indicating a strong commitment to exploration and development [4] - Skyharbour holds a diverse portfolio of uranium exploration projects covering over 662,887 hectares, positioning itself to benefit from improving uranium market fundamentals [7][8] Joint Ventures and Partnerships - Skyharbour has established joint ventures with industry leaders such as Denison Mines and Orano Canada Inc., enhancing its exploration capabilities and financial backing [9] - The company has signed earn-in option agreements with partners that could lead to over $76 million in partner-funded exploration expenditures and over $42 million in cash and share payments [9] Marketing Engagement - Skyharbour has engaged Market One Media Group for a 12-month marketing campaign at a cost of CAD $75,000, aimed at enhancing its visibility in the capital markets [5] Stock Options - The company has granted 300,000 incentive stock options to Rob Chang, exercisable at $0.45 per share for five years, aligning his interests with those of shareholders [6]

Core Insights - ProMIS Neurosciences has completed enrollment for its PRECISE-AD Phase 1b trial, with 144 patients enrolled, exceeding the target of 128, indicating strong interest in PMN310's therapeutic potential [3][8] - The company reported a net loss of $39.7 million for the year ended December 31, 2025, with cash reserves of $6.1 million, reflecting its investment in advancing the PRECISE-AD trial [12][24] - PMN310 has shown a favorable safety profile with no treatment-related serious adverse events reported to date, and it is designed to minimize treatment-related side effects, particularly Amyloid-Related Imaging Abnormalities (ARIA) [4][15] Clinical Development - The PRECISE-AD trial is expected to complete six-month assessments in Q2 2026, with a blinded interim analysis anticipated in early Q3 2026 and top-line data expected in early 2027 [1][9] - PMN310 has been granted Fast Track Designation by the FDA, which may facilitate its development and regulatory engagement [7][15] - The company is also developing a subcutaneous formulation of PMN310 to improve patient experience and strengthen its competitive profile [6][13] Financial Overview - The company closed a financing round in early 2026, raising up to $175 million, which includes $75 million upfront and $100 million tied to future warrant exercises, providing a cash runway through 2027 [6][12] - Research and development expenses for 2025 were $33.4 million, significantly higher than the $10.6 million in 2024, primarily due to costs associated with the PRECISE-AD trial [12][24] - General and administrative expenses increased to $6.8 million in 2025 from $6.2 million in 2024, driven by a moderate increase in employee headcount [12][24] Pipeline and Future Directions - PMN267 and PMN442 are other key pipeline candidates targeting amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), respectively, with PMN267 showing selectivity for pathogenic TDP-43 and PMN442 targeting alpha-synuclein [13][14] - The company is monitoring developments in preclinical and asymptomatic Alzheimer's disease trials, considering potential expansion into these areas based on PMN310's safety profile [8]

Core Insights - Kaltura has achieved ISO/IEC 42001 certification, validating its approach to secure and responsible AI management across enterprise workflows [1][2][3] - The certification highlights Kaltura's commitment to proactively identifying and mitigating AI-related risks, ensuring that AI adoption is consistent, measurable, and scalable [1][2] Group 1: Certification and Standards - ISO/IEC 42001 is the first global standard dedicated to AI management, providing a framework for governance, risk management, transparency, and accountability across the AI lifecycle [2] - Kaltura's compliance with this standard ensures that customers relying on its AI solutions are protected with high security standards [3] Group 2: Industry Impact and Applications - The certification is particularly significant for Kaltura as it serves highly regulated industries such as financial services and healthcare, where rigorous standards are critical [2][3] - Kaltura's AI-driven solutions support various applications, including personalized account guidance, patient education, and proactive service interactions, which are essential for customers in regulated sectors [3] Group 3: Company Mission and Offerings - Kaltura's mission is to enhance digital experiences across various organizational journeys, combining intelligent content creation and multimodal engagement capabilities [4] - The company serves a diverse range of clients, including leading enterprises, financial institutions, educational institutions, and media providers worldwide [4]

Core Insights - Purple Biotech has announced a collaboration with Converge Bio to enhance its tri-specific antibody platform using generative AI for oncology applications [1][3] - The collaboration aims to accelerate drug discovery timelines and improve the quality of therapeutic candidates targeting solid tumors [1][4] Company Overview - Purple Biotech is a clinical-stage company focused on developing next-generation immunotherapy platforms that maximize anti-cancer potency while minimizing toxicity [9] - The company's lead program, CAPTN-3, involves masked tri-specific antibodies that engage both T cells and NK cells, enhancing therapeutic efficacy [8][9] Collaboration Details - The partnership will leverage Converge Bio's AI platform, which integrates large-scale biological data with predictive modeling to optimize antibody candidates [3][5] - This collaboration is expected to expand Purple Biotech's pipeline with high-quality candidates while reducing development timelines [4][6] Technology and Innovation - The CAPTN-3 platform utilizes proprietary capping technology to confine immune activation to the tumor microenvironment, significantly improving the therapeutic window compared to traditional T-cell engagers [8][9] - The collaboration aims to develop novel T cell engagers that combine optimal functional properties with favorable physicochemical characteristics [3][4] Strategic Goals - The integration of AI into Purple Biotech's development strategy positions the company at the forefront of innovation in multi-specific antibody therapies [3][5] - The collaboration is seen as a strategic expansion to address additional high-value oncology targets and resistance mechanisms [6]

Core Insights - Cartier Resources Inc. has announced significant results from its drilling program at the Cadillac Project, indicating the discovery of a new style of gold mineralization related to porphyritic intrusions within the Pontiac sedimentary Group, which is largely underexplored [1][4][6] Strategic Highlights from Hope Sector - The Hope Sector has confirmed a new porphyry gold system, with drill holes CA26-327, CA26-330, CA26-331, and CA26-332 showing promising gold grades, including 5.2 g/t Au over 5.0 m and 1.2 g/t Au over 25.5 m [5][7][19] - The presence of two porphyritic felsic intrusions (Porphyry 1 and 2) suggests a significant exploration opportunity, with the mineralization extending over a minimum of 750 m in strike length and 250 m in depth [5][11] Next Steps - The company plans to revise its 2026 drilling strategy to focus on the newly identified porphyry systems and will conduct additional exploration drilling to test high-priority geophysical targets, including a 1,500 m chargeability anomaly and a 750 m magnetic anomaly [4][11][12] Geological Potential - The Hope Sector represents a fourth distinct style of gold mineralization at the Cadillac Project, expanding its geological potential beyond previously recognized systems [6][11] - The geological setting is comparable to the Canadian Malartic Camp, indicating a favorable environment for large-scale gold mineralization [1][4] Exploration Program - Cartier is undertaking a 100,000 m drilling program from Q3 2025 to Q2 2027, aiming to expand known gold zones and explore new high-potential targets along the Cadillac Fault Zone [13][15] - The company is also conducting environmental baseline studies and metallurgical sampling to assess the economic potential of the Chimo mine tailings and optimize project development [16][17] Resource Estimates - The Cadillac Project currently has a total gold resource of 767,800 ounces in the measured and indicated category and 2,416,900 ounces in the inferred category, highlighting its significant potential for gold production [27]

Findings provide early evidence supporting potential disease-modifying activity of AP01 (inhaled pirfenidone) in patients with IPFBOSTON, March 25, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., (“Avalyn” or the “Company”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced the peer-reviewed publication of data demonstrating that improvements in quantitative lung imaging correlate with lung function ...

Core Viewpoint - Aduro Clean Technologies Inc. has entered into an agreement with Water Tower Research LLC to enhance its visibility and support its growth objectives within the institutional investment community [1][4]. Group 1: Agreement Details - The agreement with Water Tower Research LLC will provide research and capital markets communications services for an initial term of six months starting April 1, 2026 [2]. - Aduro will pay a cash fee of US$39,000 (plus applicable taxes) upon execution of the agreement, with an option to renew for an additional six months at a fee of US$48,000 (plus applicable taxes) [2]. Group 2: Company and Technology Overview - Aduro Clean Technologies specializes in developing patented water-based technologies for recycling waste plastics, converting heavy crude and bitumen into lighter oil, and transforming renewable oils into higher-value fuels or chemicals [5]. - The company's Hydrochemolytic™ Technology utilizes water as a key agent in a low-temperature chemistry platform, aiming to convert low-value feedstocks into valuable resources for the 21st century [5]. Group 3: Water Tower Research LLC - Water Tower Research is an investor engagement and research-driven communications firm that focuses on modernizing investor engagement and providing open-access, institutional-quality research [5]. - The firm aims to facilitate effective communication between companies and the investment community through strategic investor engagement services [5].